PET Imaging in Patients With Suspected Cardiac Sarcoidosis (NCT03746847) | Clinical Trial Compass
CompletedNot Applicable
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
United States20 participantsStarted 2018-12-01
Plain-language summary
Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and after treatment using an imaging scan called Positron Emission Tomography / Computed Tomography (PET/CT). Investigators are doing this research study to find out if DOTATATE can help doctors diagnose people with cardiac (heart) sarcoidosis better as well as serve as a follow-up monitoring tool for a response to therapy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants will be ≥ 18 years of age
✓. History of biopsy-proven sarcoidosis OR suspected sarcoidosis based on standard clinical imaging (e.g. FDG PET/CT, MRI) without biopsy confirmation
✓. Clinical suspicion of cardiac involvement defined as the presence of any of the following:
✓. High degree A-V nodal block
✓. Complete bundle branch block
✓. Reduced left or right ventricular systolic fusion
✓. Any cardiac arrhythmia
✓. Chest pain, dyspnea or syncope without clear etiology
Exclusion criteria
✕. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.
✕. Currently on total parenteral nutrition (TPN)
✕. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
✕. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study